MedPage TodayIL-6 Blocker Stops RA Joint DamageMedPage TodayThe authors noted that it remains to be seen if other biologics such as rituximab (Rituxan) and abatacept (Orencia) also have these dissociative effects on radiographic and clinical outcomes. …
Transplantation bei Kindern: Blutgruppen-Inkompatibilität lässt sich überwindenPabst Science Publishers… parallel entfernte eine mehrfache Immunabsorption die (für Abstoßungen mitverantwortlichen) Isoagglutinine; und gleichzeitig wurde eine vier…
Biovest seeks Canadian marketing nod for its personalized lymphoma cancer …pharmabiz.comWhile combination rituximab-chemotherapy regimens available today often induce tumour remissions in the early stages of treatment, these remissions seldom last; m…
RA Today: The Outlook Improves, A Clinical Context ReportMedPage TodayNumerous treatment options for RA exist, including non-steroidal anti-inflammatory drugs, methotrexate, plaquenil, sulfasalazine, steroids, tumor necrosis factor inhibitors, and ritu…
Review of Research with Chimpanzee Models Points to Few Areas of NeedGenetic Engineering NewsRituximab, which treats B-cell non-Hodgkin lymphoma, and Remicaid, approved for several inflammatory and arthritic conditions, were tested in chimpanzees. Asid…
Biologic Fails in Kidney DisorderMedPage TodayThe addition of rituximab (Rituxan) to a standard immunosuppressive regimen failed to increase the overall response rate among patients with lupus nephritis. Note that adverse event rates overall were simil…
Biogen Idec Gearing Up For Major LaunchesSeeking AlphaBiogen also benefits from the fact that two of its potential competitors – daclizumab and ocrelizumab – are partnered programs with Abbott (ABT) and Roche (RHHBY.PK), respectively, and Biogen contro…
ACR Updates RA Advice on DMARDS, Biologics, Switching DrugsMedscapeDr. Singh pointed to 4 major changes from the 2008 ACR recommendations: The 2012 recommendations cover 3 additional biologics (certolizumab, tocilizumab, and golimumab) in addition to a…
GoLocalProvNEW: EpiVax Gets $2.25M From National Institutes of HealthGoLocalProvAlso known as biotherapeutics, drugs such as Campath, Rituximab, enzyme replacement therapies such as Myozyme, and blood factors such as FVIII often induce antibodies, rend…
Biovest to Seek Marketing Approval for BiovaxID® Personalized Lymphoma Cancer …National PostWhile combination rituximab-chemotherapy regimens available today often induce tumor remissions in the early stages of treatment, these remissions seldom las…